Complete Reversal of ABCG2-Depending Atypical Multidrug Resistance by RNA Interference in Human Carcinoma Cells

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Oligonucleotides

• Publication date

  2006-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/oli.2006.16.263PMID 16978089
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II‐targeting drugs

  2006cited by this paper
• MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance.

  2006cited by this paper
• Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.

  2005influential reference
• Induction of the ABC-Transporters Mdr1/P-gp (Abcb1), Mrp1 (Abcc1), and Bcrp (Abcg2) during Establishment of Multidrug Resistance Following Exposure to Mitoxantrone

  2005cited by this paper
• Potential applications of RNA interference technology in the treatment of cancer.

  2005influential reference
• Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.

  2005cited by this paper
• Mechanisms of gene silencing by double-stranded RNA

  2004cited by this paper
• Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.

  2004cited by this paper
• Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells

  2004cited by this paper
• Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells

  2004influential reference
• Effective knock down of very high ABCG2 expression by a hammerhead ribozyme.

  2004influential reference
• Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference

  2004cited by this paper
• Association of genomic imbalances with drug resistance and thermoresistance in human gastric carcinoma cells

  2003cited by this paper
• Multidrug resistance reversal agents.

  2003cited by this paper
• Molecular Analysis of Therapy Resistance in Gastric Cancer

  2003cited by this paper
• The reversal of multidrug resistance: an update

  2003cited by this paper
• ABC-transporters: implications on drug resistance from microorganisms to human cancers.

  2003cited by this paper
• Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)

  2003influential reference
• The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides.

  2003cited by this paper
• The reversal of multidrug resistance: an update.

  2003cited by this paper
• Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

  2003cited by this paper
• Characterization of a supernumerary ring chromosome 1 mosaicism in two cell systems by molecular cytogenetic techniques and review of the literature

  2003cited by this paper
• A System for Stable Expression of Short Interfering RNAs in Mammalian Cells

  2002cited by this paper
• Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2

  2002influential reference
• Mechanisms of cancer drug resistance.

  2002cited by this paper
• Identification of essential genes in cultured mammalian cells using small interfering RNAs.

  2001cited by this paper
• Nonviral in vivo gene delivery into tumors using a novel low volume jet-injection technology

  2001cited by this paper
• Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

  2001influential reference
• The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

  2001cited by this paper
• Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance–associated ABC transporter BCRP/MXR/ABCG2

  2001cited by this paper
• Effect of the breast-cancer resistance protein on atypical multidrug resistance.

  2000cited by this paper
• Production of first generation adenovirus vectors: a review

  2000cited by this paper
• A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1

  2000cited by this paper
• A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

  1998cited by this paper
• Decreased drug accumulation in a mitoxantrone‐resistant gastric carcinoma cell line in the absence of P‐glycoprotein

  1997cited by this paper
• Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.

  1992influential reference
• Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein.

  1990influential reference
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257.

  1990cited by this paper
• Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies.

  1970cited by this paper

• Strategies to enhance the response of liver cancer to pharmacological treatments.

  2024cites this paper
• Liver and gastrointestinal cancers

  2020cites this paper
• Computational Prediction of Drug Responses in Cancer Cell Lines From Cancer Omics and Detection of Drug Effectiveness Related Methylation Sites

  2020cites this paper
• Methylation of drug resistance‐related genes in chemotherapy‐sensitive Epstein–Barr virus‐associated gastric cancer

  2019cites this paper
• Cell Migration Related to MDR—Another Impediment to Effective Chemotherapy?

  2018cites this paper
• Bacteria-mediated delivery of RNAi effector molecules against viral HPV16-E7 eradicates oral squamous carcinoma cells (OSCC) via apoptosis

  2018cites this paper
• GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers

  2017cites this paper
• Targeting CD133+ laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles

  2016cites this paper
• Analysis of ABCG2 methylation in stool samples of Chinese healthy males by pyrosequencing.

  2016cites this paper
• New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies

  2015cites this paper
• Identification et mécanisme d'action de modulateurs sélectifs du transporteur ABCG2 responsable de la chimiorésistance de cellules cancéreuses

  2014cites this paper
• Physiological modulation approaches to improve cancer chemotherapy : a review.

  2014cites this paper
• Nanotechnology for Cancer Diagnostics and Therapy - An Update on Novel Molecular Players

  2014cites this paper
• An overview of ABC and SLC drug transporter gene regulation.

  2013cites this paper
• [Analysis of BCRP expression in breast cancer patients].

  2012cites this paper
• Evaluation of transforming potential of selected pesticide and intervention of carcinogenesis through RNA silencing and phytochemicals

  2012cites this paper
• Delivery of RNAi Effectors by tkRNAi

  2012cites this paper
• Human ABCG2: structure, function, and its role in multidrug resistance.

  2012cites this paper
• The prognostic value of breast cancer resistance protein (BCRB/ABCG2) expression in breast carcinomas.

  2012cites this paper
• Contributions of TM5, ECL3 and TM6 of human BCRP to its oligomerization activities and transport functions

  2011cites this paper
• Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine.

  2011cites this paper
• Downregulation of CD44 reduces doxorubicin resistance of CD44+CD24− breast cancer cells

  2011cites this paper
• Future prospect of RNA interference for cancer therapies.

  2010cites this paper
• Identification of the Efflux Transporter of the Fluoroquinolone Antibiotic Ciprofloxacin in Murine Macrophages: Studies with Ciprofloxacin-Resistant Cells

  2009cites this paper
• Silencing the Breast Cancer Resistance Protein Expression and Function in Caco-2 Cells Using Lentiviral Vector-Based Short Hairpin RNA

  2009cites this paper
• Therapeutic potential of RNA interference in drug-resistant cancers.

  2009cites this paper
• Silencing the breast cancer resistance protein (BCRP) expression and function in Caco-2 cells using lentiviral vector-based shRNA

  2008cites this paper
• Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe

  2008cites this paper
• Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.

  2008cites this paper
• Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

  2008cites this paper
• Dihydropyridines and atypical MDR: a novel perspective of designing general reversal agents for both typical and atypical MDR.

  2008cites this paper
• Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges

  2008cites this paper
• Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA.

  2008cites this paper
• Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.

  2007cites this paper
• Überwindung der P-Glykoprotein (MDR1)-abhängigen Multidrugresistenz mittels RNA-Interferenz

  2007cites this paper
• Small interfering RNA in drug metabolism and transport.

  2007cites this paper
• Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1.

  2007cites this paper
• RNA Interference against MDR 1 but not MRP 1 Reverses Drug Resistance in Human Small-Cell Lung Cancer Cells

  2007cites this paper
• Silencing of breast cancer resistance protein expression by lentiviral shRNA transduction particles in Caco-2 cells

  2006cites this paper
• Modulation unterschiedlicher Formen der Multidrug-Resistenz mittels eines Multitargetmultiribozymes

  2006cites this paper
• RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.

  2006cites this paper